DAKLINZA Drug Patent Profile
✉ Email this page to a colleague
When do Daklinza patents expire, and when can generic versions of Daklinza launch?
Daklinza is a drug marketed by Bristol-myers Squibb and is included in one NDA. There are five patents protecting this drug.
This drug has ninety-three patent family members in thirty-one countries.
The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this compound. Additional details are available on the daclatasvir dihydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Daklinza
Daklinza was eligible for patent challenges on July 24, 2019.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 13, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DAKLINZA?
- What are the global sales for DAKLINZA?
- What is Average Wholesale Price for DAKLINZA?
Summary for DAKLINZA
International Patents: | 93 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 128 |
Clinical Trials: | 13 |
Patent Applications: | 4 |
Drug Prices: | Drug price information for DAKLINZA |
DailyMed Link: | DAKLINZA at DailyMed |


DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for DAKLINZA
Generic Entry Date for DAKLINZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for DAKLINZA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ain Shams University | Phase 3 |
Cairo University | Phase 3 |
Tanta University | Phase 2/Phase 3 |
US Patents and Regulatory Information for DAKLINZA
DAKLINZA is protected by eight US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of DAKLINZA is ⤷ Try for Free.
This potential generic entry date is based on patent ⤷ Try for Free.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
International Patents for DAKLINZA
When does loss-of-exclusivity occur for DAKLINZA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 0016
Patent: FORMA CRISTALINA DE LA SAL DICLORHIDRATO DE ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METOXICARBONIL)AMINO)-3-METILBUTANO IL)-2-PIRROLIDINIL)-1H-IMIDAZOL-5-IL)-4-BIFENILIL)-1H-IMIDAZOL-2-IL)-1-PIRROLIDINIL)CARBONIL)-2-METILPROPIL)CARBAMATO DE METILO
Estimated Expiration: ⤷ Try for Free
Patent: 4566
Patent: FORMA CRISTALINA DE LA SAL DICLORHIDRATO DE ((1S)-1-(((2S)-2-(5-(4-(2-((2S)-1-((2S)-2-((METOXICARBONIL)AMINO)-3-METILBUTANOIL)-2-PIRROLIDINIL)-1H-IMIDAZOL-5-IL)-4-BIFENILIL)-1H-IMIDAZOL-2-IL)-1-PIRROLIDINIL)CARBONIL)-2-METILPROPIL)CARBAMATO DE METILO
Estimated Expiration: ⤷ Try for Free
Australia
Patent: 08284100
Patent: Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
Estimated Expiration: ⤷ Try for Free
Brazil
Patent: 0815142
Patent: FORMA CRISTALINA DO SAL DE DICLORIDRATO ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METOXICARBONIL)-3-MET ILBUTANOIL)-2-PIRROLIDINIL)-1H-IMIDAZOL-5-IL)-4-BIFENILIL)- 1H-IMIDAZOL-2-IL)-1-PIRROLIDINIL)CARBONIL)-2-METELPROPI L)CARBAMATO DE METILA
Estimated Expiration: ⤷ Try for Free
Canada
Patent: 95729
Patent: FORME CRISTALLINE DE DIHYDROCHLORURE DE METHYL ((1S)-1-(((2S>2-(5-(4'-(2-((2S)-1-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE (CRYSTALLINE FORM OF METHYL ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SALT)
Estimated Expiration: ⤷ Try for Free
Chile
Patent: 08002354
Patent: Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo; composición y combinacion farmacéutica; y su uso para tratar la hepatitis c.
Estimated Expiration: ⤷ Try for Free
China
Patent: 1778840
Patent: Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
Estimated Expiration: ⤷ Try for Free
Colombia
Patent: 60327
Patent: FORMA CRISTALINA DE LA SAL DICLORHIDRATO DE ((2S)-2-(5-(4`-(2((2S)-1-((2S)-2-((METOXICARBONIL)AMINO)-3-METILBUTANIOL)-2-PIRROLIDINIL)-1H-IMIDAZOL-5-IL-4BIFENILIL)-1H-IMIDAZOL-2-IL)-1-PIRROLIDINIL)CARBONIL)-2-METILPROPIL)CARBAMATO DE METILO
Estimated Expiration: ⤷ Try for Free
Eurasian Patent Organization
Patent: 8152
Patent: КРИСТАЛЛИЧЕСКАЯ ФОРМА ДИГИДРОХЛОРИДА МЕТИЛ ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((МЕТОКСИКАРБОНИЛ)АМИНО)-3-МЕТИЛБУТАНОИЛ)-2-ПИРРОЛИДИНИЛ)-1Н-ИМИДАЗОЛ-5-ИЛ)-4-БИФЕНИЛИЛ)-1Н-ИМИДАЗОЛ-2-ИЛ)-1-ПИРРОЛИДИНИЛ)КАРБОНИЛ)-2-МЕТИЛПРОПИЛ)КАРБАМАТА (CRYSTALLINE FORM OF METHYL ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SALT)
Estimated Expiration: ⤷ Try for Free
Patent: 1000196
Patent: КРИСТАЛЛИЧЕСКАЯ ФОРМА ДИГИДРОХЛОРИДА МЕТИЛ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((МЕТОКСИКАРБОНИЛ)АМИНО)-3-МЕТИЛБУТАНОИЛ)-2-ПИРРОЛИДИНИЛ)-1Н-ИМИДАЗОЛ-5-ИЛ)-4-БИФЕНИЛИЛ)-1Н-ИМИДАЗОЛ-2-ИЛ)-1-ПИРРОЛИДИНИЛ)КАРБОНИЛ)-2-МЕТИЛПРОПИЛ)КАРБАМАТА
Estimated Expiration: ⤷ Try for Free
European Patent Office
Patent: 83244
Patent: FORME CRISTALLINE DE DIHYDROCHLORURE DE MÉTHYL ((1S)-1-(((2S>2-(5-(4'-(2-((2S)-1-((2S)-2-((MÉTHOXYCARBONYL)AMINO)-3-MÉTHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHÉNYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)CARBONYL)-2-MÉTHYLPROPYL)CARBAMATE (CRYSTALLINE FORM OF METHYL ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SALT)
Estimated Expiration: ⤷ Try for Free
Hong Kong
Patent: 44089
Patent: CRYSTALLINE FORM OF METHYL ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2- ((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5- YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)CARBONYL)-2- METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SALT
Estimated Expiration: ⤷ Try for Free
Israel
Patent: 3684
Patent: צורות גבישייות של מלחי מיטל ((s1) - 1 - (((s2) - 2 - (5 - ('4 (2 - ((s2) - 1 - ((s2) - 2 - ((מטוקסיקרבוניל) אמינו) - 3 - מטילביוטאנויל) - 2 - פירולידיניל) - h1 - אמידאזול - 5 - איל) - 4 - ביפניליל) - h1 - אימידאזול - 2 - איל) - 1 - פירולידיניל) קרבוניל)-2-מטילפרופיל) קרבמט דיהידרוכלור (Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt)
Estimated Expiration: ⤷ Try for Free
Japan
Patent: 44179
Estimated Expiration: ⤷ Try for Free
Patent: 10535785
Estimated Expiration: ⤷ Try for Free
Mexico
Patent: 10001368
Patent: FORMA CRISTALINA DE LA SAL DICLORHIDRATO DE ((1S)-1-(((2S)-2-(5-(4 ́-(2-((2S)-1-((2S)-2-((METOXICARBONIL) AMINO)-3-METILBUTANOIL)-2-P IRROLIDINIL)-1H-IMIDAZOL-5-IL)-4-BIFENILIL)-1H-IMIDAZOL-2-IL)-1-P IRROLIDINIL) CARBONIL)-2-METILPROPIL)CARBAMATO DE (CRYSTALLINE FORM OF METHYL ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2 S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)- 1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL )CARBONYL)-2-METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SA)
Estimated Expiration: ⤷ Try for Free
New Zealand
Patent: 3148
Patent: CRYSTALLINE FORM OF METHYL ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SALT
Estimated Expiration: ⤷ Try for Free
Peru
Patent: 090940
Patent: FORMA CRISTALINA DE LA SAL DICLORHIDRATO DE ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METOXICARBONIL)AMINO)-3-METILBUTANOIL)-2-PIRROLIDINIL)-1H-IMIDAZOL-5-IL)-4-BIFENILIL)-1H-IMIDAZOL-2-IL)-1-PIRROLIDINIL)CARBONIL)-2-METILPROPIL)CARBAMATO DE METIL
Estimated Expiration: ⤷ Try for Free
South Africa
Patent: 1000843
Patent: CRYSTALLINE FORM OF METHYL((1S)-1-(((2S)-2-(5-(4'-2-((2S)-1-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SALT
Estimated Expiration: ⤷ Try for Free
South Korea
Patent: 1508022
Estimated Expiration: ⤷ Try for Free
Patent: 100042641
Patent: CRYSTALLINE FORM OF METHYL ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SALT
Estimated Expiration: ⤷ Try for Free
Spain
Patent: 02791
Estimated Expiration: ⤷ Try for Free
Taiwan
Patent: 59813
Estimated Expiration: ⤷ Try for Free
Patent: 0911790
Patent: Crystalline form of methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
Estimated Expiration: ⤷ Try for Free
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering DAKLINZA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Eurasian Patent Organization | 200900298 | ИНГИБИТОРЫ ВИРУСА ГЕПАТИТА С | ⤷ Try for Free |
Slovenia | 2049522 | ⤷ Try for Free | |
Argentina | 070016 | FORMA CRISTALINA DE LA SAL DICLORHIDRATO DE ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METOXICARBONIL)AMINO)-3-METILBUTANO IL)-2-PIRROLIDINIL)-1H-IMIDAZOL-5-IL)-4-BIFENILIL)-1H-IMIDAZOL-2-IL)-1-PIRROLIDINIL)CARBONIL)-2-METILPROPIL)CARBAMATO DE METILO | ⤷ Try for Free |
Spain | 2662590 | ⤷ Try for Free | |
Israel | 196813 | תרכובות ביפניל ביסאימידאזול, תכשירים המכילים אותן ושימושים בהן (Biphenyl bisimidazole compounds, compositions comprising the same and uses thereof) | ⤷ Try for Free |
South Korea | 20140066768 | HEPATITIS C VIRUS INHIBITORS | ⤷ Try for Free |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DAKLINZA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2049522 | 211 50001-2015 | Slovakia | ⤷ Try for Free | PRODUCT NAME: DAKLATASVIR DIHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/939 - EU/1/14/939/004 20140826 |
2049522 | C20150003 00128 | Estonia | ⤷ Try for Free | PRODUCT NAME: DAKLATASVIIR;REG NO/DATE: EU/1/14/939 26.08.2014 |
2049522 | CA 2015 00003 | Denmark | ⤷ Try for Free | PRODUCT NAME: DACLATASVIR OG FARMACEUTISK ACCEPTABLE SALTE DERAF, SAERLIGT DACLATASVIR-DIHYDROCHLORID; REG. NO/DATE: EU/1/14/939 20140822 |
2049522 | PA2015006,C2049522 | Lithuania | ⤷ Try for Free | PRODUCT NAME: DAKLATASVIRAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, YPAC DAKLATASVIRO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/14/939/001 - EU/1/14/939/004, 2 00140822 |
2049522 | 1590007-9 | Sweden | ⤷ Try for Free | PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REG. NO/DATE: EU/1/14/939 20140826 |
2049522 | 300713 | Netherlands | ⤷ Try for Free | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for DAKLINZA
More… ↓